Evidence map›Paper›PMID 29588543›Full record

ArticleScientific reports2018

Urinary CE-MS peptide marker pattern for detection of solid tumors.

Iwona Belczacka, Agnieszka Latosinska, Justyna Siwy, Jochen Metzger, Axel S Merseburger, Harald Mischak, Antonia Vlahou, Maria Frantzi, Vera Jankowski

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Iwona BelczackaMosaiques Diagnostics GmbH, Hannover, Germany.
Agnieszka LatosinskaMosaiques Diagnostics GmbH, Hannover, Germany.
Justyna SiwyMosaiques Diagnostics GmbH, Hannover, Germany.
Jochen MetzgerMosaiques Diagnostics GmbH, Hannover, Germany.
Axel S MerseburgerDepartment of Urology, University of Lübeck, Lübeck, Germany.
Harald MischakMosaiques Diagnostics GmbH, Hannover, Germany.
Antonia VlahouBiotechnology Division, Biomedical Research Foundation, Academy of Athens (BRFAA), Athens, Greece.
Maria FrantziMosaiques Diagnostics GmbH, Hannover, Germany.
Vera JankowskiUniversity Hospital RWTH Aachen, Institute for Molecular Cardiovascular Research (IMCAR), Aachen, Germany. vjankowski@ukaachen.de.
Mosaiques Diagnostics and Therapeutics (Germany) · DERWTH Aachen University · DEBiomedical Research Foundation of the Academy of Athens · GRUniversity of Lübeck · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Urinary profiling datasets, previously acquired by capillary electrophoresis coupled to mass-spectrometry were investigated to identify a general urinary marker pattern for detection of solid tumors by targeting common systemic events associated with tumor-related inflammation. A total of 2,055 urinary profiles were analyzed, derived from a) a cancer group of patients (n = 969) with bladder, prostate, and pancreatic cancers, renal cell carcinoma, and cholangiocarcinoma and b) a control group of patients with benign diseases (n = 556), inflammatory diseases (n = 199) and healthy individuals (n = 331). Statistical analysis was conducted in a discovery set of 676 cancer cases and 744 controls. 193 peptides differing at statistically significant levels between cases and controls were selected and combined to a multi-dimensional marker pattern using support vector machine algorithms. Independent validation in a set of 635 patients (293 cancer cases and 342 controls) showed an AUC of 0.82. Inclusion of age as independent variable, significantly increased the AUC value to 0.85. Among the identified peptides were mucins, fibrinogen and collagen fragments. Further studies are planned to assess the pattern value to monitor patients for tumor recurrence. In this proof-of-concept study, a general tumor marker pattern was developed to detect cancer based on shared biomarkers, likely indicative of cancer-related features.

Indexed as

AdolescentAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Renal CellCholangiocarcinomaElectrophoresis, CapillaryHumansInflammationKidney NeoplasmsMaleMass SpectrometryMiddle AgedNeoplasm InvasivenessPancreatic NeoplasmsBiomarkers, TumorPeptides

Identifiers

PMID29588543
PMCPMC5869723
OpenAlexW2794475216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.